Novo Nordisk and Eskayef unite to manufacture modern insulin

Novo Nordisk, the world's biggest insulin maker, has teamed up with local Eskayef Pharmaceuticals to set up a state-of-the-art manufacturing facility.

The memorandum of understanding entails transfer of Novo Nordisk's proprietary state-of-the-art technology to produce human and modern insulin in cartridges to Bangladesh.

The production facility, which will be set up at a cost of Tk 300 crore, is expected to be complete in three years. 

The Danish pharmaceutical giant in partnership with Eskayef has been manufacturing human insulin vials in Bangladesh since 2012, but pen-filled modern insulin products are still imported from Denmark.

Once the facility, which will be housed at Eskayef's existing site in Tongi, is up and running, Bangladesh will be able to cut its dependence on imports.

Novo Nordisk undertakes a due and diligent process before investing in a country. 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. 

Over the years, Eskayef has emerged as one of the leading pharmaceutical companies in Bangladesh. 

Eskayef is growing globally and is already exporting its products to different countries in Asia, Africa, Europe and Australia. 

Transcom Distribution Company Ltd distributes Novo Nordisk's insulin products across the country.

Register to Attend CPhI China 2018!